Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 9/20 | 0.41 |
| ▸ | POLRMT | O00411 | 1/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.41 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.38 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.38 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10120051 | 0.92 | P2RY2 (0.42) | P2RY2POLRMTP2RY4P2RX1P2RX3 | |
| SCHEMBL10120887 | 0.88 | POLRMT (0.53) | P2RY2POLRMTP2RX1P2RX3P2RX4 | |
| SCHEMBL15998230 | 0.85 | POLRMT (0.50) | POLRMTP2RX1P2RX3P2RX4P2RX2 | |
| SCHEMBL10120060 | 0.85 | TMPRSS2 (0.41) | P2RY2POLRMTP2RY4P2RX1P2RX3 | |
| SCHEMBL10120062 | 0.85 | POLRMT (0.40) | P2RY2POLRMTP2RY4P2RX1P2RX3 | |
| SCHEMBL17719209 | 0.83 | TMPRSS2 (0.42) | P2RY2POLRMTP2RY4P2RX1P2RX3 | |
| SCHEMBL4765700 | 0.81 | POLRMT (0.38) | P2RY2POLRMTP2RY4P2RX1P2RX3 | |
| SCHEMBL4765352 | 0.80 | POLRMT (0.53) | P2RY2POLRMTP2RX1P2RX3P2RX4 | |
| SCHEMBL7598980 | 0.80 | P2RY2 (0.51) | P2RY2POLRMTP2RY4P2RX1P2RX3 | |
| SCHEMBL17522701 | 0.78 | P2RY2 (0.45) | P2RY2POLRMTP2RY4P2RX1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20150152116-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2015-06-04 | — | — | US | disclosed |
| US-20150111839-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2015-04-23 | — | — | US | disclosed |
| US-20120027752-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111839-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | P2RY2 560/4885POLRMT 148/4885P2RY4 236/4885 |
| US-20120027752-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | P2RY2 560/4885POLRMT 148/4885P2RY4 236/4885 |
| US-20150152116-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | P2RY2 560/4885POLRMT 148/4885P2RY4 236/4885 |
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | P2RY2 560/4885POLRMT 148/4885P2RY4 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.